is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS).
study enrolled 3,020 patients within 180 days of a small, subcortical, lacunar stroke at 81 sites in eight countries during 2003-2011.
trial was a randomized, multicenter clinical trial conducted in 82 clinical centers inNorth America, Latin America, and Spain.
The poor performance of this dual antiplatelet combination in this large study, called the Secondary Prevention of Small Suhcortical Strokes (SPS3
) trial, leaves the secondary stroke prevention guideline published last year by the American Heart Association and American Stroke Association unchanged in its recommendation of three antiplatelet drug options for patients with a history of stroke or transient ischemic attack: aspirin, aspirin plus dipyridamole, or clopidogrel (Stroke 2011;42:227-76), Dr.
* The Secondary Prevention of Small Subcortical Strokes (SPS3
) trial is investigating secondary prevention of subcortical stroke.
The Stroke Prevention in Small Subcortical Strokes (SPS3
) trial, an NINDS-funded study, will address this question, but the results of that trial are several years away.